Background:
Researchers want to study fluids and blood of people with cancer. The fluids are from the
abdomen and around the lungs. Studying these might help researchers learn about the
biology of cancer. This may lead to better ways to treat cancer.
Objectives:
To study the biology of cancer.
Eligibility:
Adults 18 and older with malignant solid tumors.
Design:
Participants will be screened with medical history, blood tests, and confirmation of
diagnosis.
Participants will have samples taken at regularly scheduled procedures. Fluids from the
abdomen and/or lungs will be taken as part of the procedures. Blood will be taken
separately.
Participants may be asked to give more samples at future procedures.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03189108.
Background:
-Malignant ascites or pleural effusions are often seen in patients with solid tumor
malignancies.
-Malignant ascites is proinflammatory with many cytokines present and acts to promote
tumor cell growth.
-The cellular composition of malignant ascites consists of lymphocytes, macrophages and
monocytes.
-Serum monocytes and lymphocytes play a role in the native host anti-tumor immune
mediated mechanisms.
-A paracentesis or thoracentesis is often done for symptomatic relief from the malignant
fluid collection.
Primary Objective:
-To obtain blood samples and ascites and pleural effusion samples from patients with
solid
tumor malignancies, with the intent of performing translational studies related to
cancer.
Eligibility:
- Patients greater than or equal to 18 years of age.
- Diagnosis of malignant solid tumor.
- Patients must be able and willing to provide informed consent.
Design:
-We will collect approximately 200cc-5L ascites from patients that are undergoing a
therapeutic paracentesis or thoracentesis. No thoracentesis or paracentesis will be
performed solely for research purposes.
-The fluid will be collected during the medical procedure and may be collected at more
than one time point.
-We will also collect 30ml of peripheral blood. This will be from patients who are being
seen in follow up, consultation, or presenting for enrollment on a clinical trial.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationNational Cancer Institute
Principal InvestigatorChristina Messineo Annunziata
